Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation

被引：23

作者：

Kitahara, Masaaki ^{[1
]}

Mizukoshi, Eishiro ^{[1
]}

Terashima, Takeshi ^{[1
]}

Nakagawa, Hidetoshi ^{[1
]}

Horii, Rika ^{[1
]}

Iida, Noriho ^{[1
]}

Arai, Kuniaki ^{[1
]}

Yamashita, Taro ^{[1
]}

Sakai, Yoshio ^{[1
]}

Yamashita, Tatsuya ^{[1
]}

Honda, Masao ^{[1
]}

Nakamoto, Yasunari ^{[2
]}

Kaneko, Shuichi ^{[1
]}

机构：

[1] Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan

[2] Univ Fukui, Fac Med Sci, Dept Internal Med 2, Fukui, Japan

来源：

TRANSLATIONAL ONCOLOGY | 2020年 / 13卷 / 07期

基金：

日本学术振兴会;

关键词：

PERIPHERAL-BLOOD; RECURRENCE; CANCER; IMMUNOTHERAPY; RESPONSES; ADJUVANT; SURVIVAL; DISEASE; INNATE;

D O I：

10.1016/j.tranon.2020.100777

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dendritic cell (DC)-based immunotherapies are believed to help eradicate residual tumor cells, including hepatocellular car-cinoma (HCC). Here, we assessed the safety and clinical response to OK432-stimulated monocyte-derived DCs (MoDCs) in treating HCC after radiofrequency ablation (RFA). MoDCs were derived from 30 HCC patients in the presence of interleukin-4 and granulocyte-macrophage colony stimulating factor for 5 days and then cultured for 2 more days in the medium (basic protocol) or stimulated with OK432. On day 7, DCs were harvested and percutaneously injected into HCC tumors after RFA. We observed no grade 3 or 4 National Cancer Institute Common Toxicity Criteria adverse events. Kaplan-Meier analysis in-dicated that patients treated with RFA + OK432-stimulated DCs transfer had longer recurrence-free survival than those treated with RFA + basic-protocol DCs (median: 24.8 vs 13.0 months; P = .003). RFA with DC infusion can enhance var-ious tumor-associated antigen (TAA)-speci fic T-cell responses. Additionally, the 5-year RFS rate for patients with signi fi-cantly increased TAA-speci fic T-cell responses was much higher than for other patients (50.0% vs. 7.7%; P = .030). Our study provides useful information for development of HCC immunotherapies (trial registration: UMIN000001701).

引用

页数：6

共 34 条

[1] Clinical use of dendritic cells for cancer therapy [J].